MTA-based personalized vaccine

The **MTA-based personalized vaccine** is an investigational personalized neoantigen vaccine (PNV) developed by Dr. Adilia Hormigo and colleagues at the Icahn School of Medicine at Mount Sinai and Montefiore Einstein. It is designed for the treatment of newly diagnosed glioblastoma. The vaccine utilizes the **OpenVax** computational pipeline to identify up to ten patient-specific mutation-derived tumor antigens (MTAs), or neoantigens, from the individual's tumor sequencing data. These MTAs are synthesized as long peptides and administered to stimulate a robust T-cell immune response against the unique somatic mutations of the patient's tumor. By targeting these tumor-specific antigens, the vaccine aims to reverse the characteristic immunosuppressive microenvironment of glioblastoma. In clinical evaluation (NCT03223103), the vaccine is administered in combination with the adjuvant **Poly-ICLC** and standard care treatments, including temozolomide and Tumor Treating Fields (TTFields).

Other names

Personalized Mutation-derived Tumor Antigen VaccineMTA-based vaccinePersonalized neoantigen vaccinePNV